MAX Chat
Company Analysis RaQualia Pharma Inc.
1. Summary
Advantages
- The stock's return over the last year (21.48%) is higher than the sector average (0%).
Disadvantages
- Price (623 Β₯) is higher than fair price (593.28 Β₯)
- Dividends (0%) are below the sector average (1.76%).
- Current debt level 35.76% has increased over 5 years from 0.0496%.
- The company's current efficiency (ROE=-8.47%) is lower than the sector average (ROE=1.54%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| RaQualia Pharma Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -11.3% | 0% | 0.4% |
| 90 days | -11.9% | 0% | 14.3% |
| 1 year | 21.5% | 0% | 12.7% |
4579 vs Sector: RaQualia Pharma Inc. has outperformed the "Healthcare" sector by 21.48% over the past year.
4579 vs Market: RaQualia Pharma Inc. has outperformed the market by 8.8% over the past year.
Stable price: 4579 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4579 with weekly volatility of 0.413% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (623 Β₯) is higher than the fair price (593.28 Β₯).
Price is higher than fair: The current price (623 Β₯) is 4.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (-24.49) is lower than that of the sector as a whole (72.5).
P/E vs Market: The company's P/E (-24.49) is lower than that of the market as a whole (145.33).
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.49) is lower than that of the sector as a whole (69.35).
P/BV vs Market: The company's P/BV (1.49) is lower than that of the market as a whole (148.5).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.67) is lower than that of the sector as a whole (89.6).
P/S vs Market: The company's P/S indicator (2.67) is lower than that of the market as a whole (149.54).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (45.8) is higher than that of the sector as a whole (28.83).
EV/Ebitda vs Market: The company's EV/Ebitda (45.8) is lower than that of the market as a whole (147.75).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -3.69% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-3.69%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.45%).
5.4. ROE
ROE vs Sector: The company's ROE (-8.47%) is lower than that of the sector as a whole (1.54%).
ROE vs Market: The company's ROE (-8.47%) is lower than that of the market as a whole (9.43%).
5.5. ROA
ROA vs Sector: The company's ROA (-5.99%) is lower than that of the sector as a whole (0.9718%).
ROA vs Market: The company's ROA (-5.99%) is lower than that of the market as a whole (4.67%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (8.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
